These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 515108)

  • 1. [The usefulness of compartmental analysis for the development of sustained release drug forms; experiences with drotaverine in humans].
    Rutz-Coudray MH; Balant L; Buri P
    Pharm Acta Helv; 1979; 54(7-8):210-3. PubMed ID: 515108
    [No Abstract]   [Full Text] [Related]  

  • 2. Absorption of sustained-release and plain papaverine in man.
    Kanto J; Iisalo E; Manell D; Mäntylä R
    Int J Clin Pharmacol Biopharm; 1979 Sep; 17(9):375-7. PubMed ID: 500258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The pharmacokinetics of papaverine and its bioavailability from a sustained-action preparation].
    Juhran VW; Haase W; Götz R; Fleissig W
    Arzneimittelforschung; 1975 May; 25(5):771-3. PubMed ID: 1242319
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prolonged liberation, by inclusion in an inert matrix, of drotaverine coprecipitate].
    Rutz-Coudray MH; Giust J; Buri P
    Pharm Acta Helv; 1979; 54(12):363-5. PubMed ID: 538043
    [No Abstract]   [Full Text] [Related]  

  • 5. Sustained-release papaverine hydrochloride.
    Kostenbauder HB
    J Am Pharm Assoc; 1977 May; 17(5):303-6. PubMed ID: 874257
    [No Abstract]   [Full Text] [Related]  

  • 6. Papaverine blood levels after administration of a sustained-release preparation. Short communication.
    Maggi GC; Cerchiari D; Coppi G
    Arzneimittelforschung; 1977; 27(6):1214-5. PubMed ID: 578446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The fate of drotaverine-acephyllinate in rat and man. II. Human pharmacokinetics of drotaverine-14C-acephyllinate.
    Vargay Z; Deutsch T; Szatmári I; Szüts T; Várkonyi P; Kerpel-Fronius S; Eckhardt S
    Eur J Drug Metab Pharmacokinet; 1984; 9(1):17-29. PubMed ID: 6546919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absorption, distribution and elimination of drotaverine.
    Magyar K; Lengyel M; Knoll J
    Acta Physiol Acad Sci Hung; 1978; 51(4):401-11. PubMed ID: 754481
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of soft gelatin capsule vs. sustained release formulation of papaverine HCl: vasodilation and plasma levels.
    Lee BY; Sakamoto H; Trainor F; Brody G; Cho YW
    Int J Clin Pharmacol Biopharm; 1978 Jan; 16(1):32-9. PubMed ID: 631969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative and quantitative determination of drotaverine metabolites in rat bile.
    Vargay Z; Simon G; Winter M; Szüts T
    Eur J Drug Metab Pharmacokinet; 1980; 5(2):69-74. PubMed ID: 7398679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biopharmaceutical aspects of Depogen.
    Szentmiklósi P; Marton S
    Pharmazie; 1983 Sep; 38(9):611-3. PubMed ID: 6647534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of papaverine hydrochloride and the biopharmaceutics of its oral dosage forms.
    Garrett ER; Roseboom H; Green JR; Schuermann W
    Int J Clin Pharmacol Biopharm; 1978 May; 16(5):193-208. PubMed ID: 649238
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurogenic component in the effect of papaverine, drotaverine and bencyclane.
    Minker E; Blazsó G; Végh A; Gerö L
    Acta Biol Hung; 1983; 34(2-3):247-55. PubMed ID: 6320560
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Some anomalies in the L-DOPA response: recent biochemical studies.
    Sandler M
    Adv Neurol; 1974; 5():259-63. PubMed ID: 4440575
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapeutic experiences with Paveron solution injections in angina pectoris].
    Brecht F
    Med Welt; 1973 Jan; 24(4):141-2. PubMed ID: 4617090
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between disintegration, dissolution and in vivo absorption rate in the case of compounds with benzyl-isoquinoline structures and its pharmacokinetic aspects.
    Marton S; Szentmiklósi P; Rácz I
    Pol J Pharmacol Pharm; 1984; 36(4):385-95. PubMed ID: 6527970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Application of new membrane selective electrodes for the determination of drotaverine hydrochloride in tablets and plasma.
    El-Saharty YS; Metwaly FH; Refaat M; El-Khateeb SZ
    J Pharm Biomed Anal; 2006 Jun; 41(3):720-4. PubMed ID: 16469468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Controlled-release drug delivery systems and sustained preparations].
    Xi NZ
    Yao Xue Xue Bao; 1984 Sep; 19(9):715-9. PubMed ID: 6536186
    [No Abstract]   [Full Text] [Related]  

  • 19. Conception of peroral sustained-release dosage forms: calculation of initial and maintenance dose with consideration of accumulation.
    Förster H; Lippold BC
    Pharm Acta Helv; 1982; 57(12):345-9. PubMed ID: 7156173
    [No Abstract]   [Full Text] [Related]  

  • 20. Spectrophotometric determination of pipazethate HCl, dextromethorphan HBr and drotaverine HCl in their pharmaceutical preparations.
    Amin AS; El-Sheikh R; Zahran F; Gouda AA
    Spectrochim Acta A Mol Biomol Spectrosc; 2007 Jul; 67(3-4):1088-93. PubMed ID: 17092767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.